Amoxicillin-Clavulanate 1g Duration
For most adult infections, amoxicillin-clavulanate 1g should be administered for 5-7 days, with specific exceptions requiring longer courses based on infection type and patient age.
Duration by Indication
Acute Bacterial Rhinosinusitis (ABRS)
- Adults: 5-7 days is the recommended duration for uncomplicated ABRS 1
- Children: 10-14 days remains the standard despite shorter adult courses 1
- The 2012 IDSA guideline specifically supports this shorter adult duration based on moderate-quality evidence
Community-Acquired Pneumonia (CAP)
- 5-7 days for low to moderate severity CAP in adults, provided the patient is afebrile for 48 hours and clinically stable 2
- Clinical stability criteria include: temperature ≤37.8°C, heart rate ≤100 bpm, respiratory rate ≤24 breaths/min, systolic BP ≥90 mmHg, oxygen saturation ≥90%, ability to maintain oral intake, and normal mental status
- Continue until the patient is well for 7 days (generally 10-14 days total) for respiratory tract infections 3
Chronic Rhinosinusitis
- 14 days (3 weeks in some studies) for chronic rhinosinusitis based on comparative trials 4
- Studies used amoxicillin-clavulanate 625mg three times daily for 3 weeks with comparable efficacy to other regimens
Lower Respiratory Tract Infections (COPD Exacerbations)
- At least 7 days for community-acquired lower respiratory tract infections managed in hospital settings 3
- Assess clinical response at day 5-7 for improvement of symptoms
Key Dosing Considerations
Standard Adult Dosing (FDA-Approved) 5
- Mild-moderate infections: 500mg/125mg every 12 hours OR 250mg/125mg every 8 hours
- Severe infections/respiratory tract: 875mg/125mg every 12 hours OR 500mg/125mg every 8 hours
- The 1g dose referenced in your question likely refers to the 875mg/125mg formulation (total ~1000mg)
High-Dose Regimens
When treating infections with suspected resistant pathogens (recent antibiotic use within 4-6 weeks, high local resistance rates):
Important Clinical Caveats
Shorter courses (5-7 days) are appropriate when:
- Patient demonstrates clinical improvement within 72 hours
- No risk factors for resistant organisms
- Adequate source control achieved
- Patient reaches clinical stability criteria
Longer courses (10-14 days) are necessary for:
- Pediatric patients with ABRS or acute otitis media 1, 6
- Patients not improving after initial 3-5 days of therapy 7
- Severe infections or immunocompromised hosts
- Suspected Legionella pneumophila (requires 21 days) 3
Common pitfall: The evidence strongly supports that 10-day courses may be unnecessarily long for many adult infections, yet many clinicians default to this duration. The 2012 IDSA guideline explicitly recommends 5-7 days for adult ABRS, representing a significant departure from older 10-14 day recommendations 1. However, this shorter duration does NOT apply to children, where 10-14 days remains standard due to different pharmacokinetics and immune responses.
Renal adjustment required: Patients with GFR <30 mL/min should not receive the 875mg/125mg dose and require dosing modifications 5.